SCHEMBL24875255

SCHEMBL24875255

COC(=O)Cc1cc(F)ccc1Cl

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 2/20 0.45
ANO1 Q5XXA6 1/20 0.44
HTR2A P28223 3/20 0.44
SLC6A4 P31645 3/20 0.44
KCNH2 Q12809 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.42
ROCK2 O75116 1/20 0.41
ROCK1 Q13464 1/20 0.41
SGMS2 Q8NHU3 1/20 0.41
KDM4E B2RXH2 1/20 0.40
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PTGER3 P43115 1/20 0.40
MEN1 O00255 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30192787 1.00 P2RX7 (0.45) P2RX7ANO1HTR2ASLC6A4KCNH2
SCHEMBL30197770 0.87 P2RX7 (0.48) P2RX7KDM4EL3MBTL1MAPTKMT2A
SCHEMBL837237 0.87 P2RX7 (0.48) P2RX7KDM4EL3MBTL1MAPTKMT2A
SCHEMBL8063678 0.83 MAPK8 (0.46) ANO1SMN1; SMN2MEN1MAPTKMT2A
SCHEMBL7133160 0.83 MAPT (0.49) P2RX7KDM4EGAAL3MBTL1MEN1
SCHEMBL24097694 0.81 EGFR (0.55) ANO1SMN1; SMN2KDM4EGAAL3MBTL1
SCHEMBL23362766 0.81 SMN1; SMN2 (0.52) SMN1; SMN2GAAMEN1MAPTKMT2A
SCHEMBL8251121 0.81 SMN1; SMN2 (0.43) HTR2ASLC6A4KCNH2SMN1; SMN2SGMS2
SCHEMBL30296102 0.81 SMN1; SMN2 (0.52) SMN1; SMN2GAAMEN1MAPTKMT2A
SCHEMBL2978593 0.81 EGFR (0.55) ANO1KDM4EGAAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376056-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. 2024-11-14 US disclosed
EP-4366829-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF Dice Alpha, Inc. (US) 2024-05-15 EP disclosed
CN-117957212-A IL-17A modulators based on phenylacetamide and uses thereof 戴斯阿尔法公司 2024-04-30 CN disclosed
CN-117881683-A PI3K alpha inhibitors and methods of use thereof 传达治疗有限公司 2024-04-12 CN disclosed
WO-2023288242-A1 PI3Kα INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. (US) 2023-01-19 WO disclosed
WO-2023283453-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2023-01-12 WO disclosed
WO-2023283453-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2023-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376056-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF IL17A, IL1A, IL2 P2RX7 681/4885ANO1 3937/4885HTR2A 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.